F. A. Romero

发表

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

F. A. Romero, Christopher Jones, Yingzi Xu, 2020, Journal of medicinal chemistry.

Fragment-Based Discovery of a Selective and Cell-Active Benzodiazepinone CBP/EP300 Bromodomain Inhibitor (CPI-637).

Y. Leblanc, H. Jayaram, R. Sims, 2016, ACS medicinal chemistry letters.

Potent and Selective α-Ketoheterocycle-Based Inhibitors of the Anandamide and Oleamide Catabolizing Enzyme, Fatty Acid Amide Hydrolase

Benjamin F. Cravatt, Dale L. Boger, D. Boger, 2007 .

GNE-371, a Potent and Selective Chemical Probe for the Second Bromodomains of Human Transcription-Initiation-Factor TFIID Subunit 1 and Transcription-Initiation-Factor TFIID Subunit 1-like.

H. Jayaram, F. A. Romero, R. Cummings, 2018, Journal of medicinal chemistry.

Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance.

D. Stokoe, P. Sandy, Steffan Vartanian, 2017, Bioorganic & medicinal chemistry letters.

Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.

Andrew C Good, Vickie Tsui, Jian Wang, 2016, Journal of medicinal chemistry.

Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling.

Adam R. Johnson, N. C. Ray, Rohan V Mendonca, 2019, Bioorganic & medicinal chemistry letters.

Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation.

Karen E Gascoigne, Z. Modrušan, D. Arnott, 2019, Cell reports.

A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.

Fei Wang, H. Jayaram, F. A. Romero, 2017, Journal of medicinal chemistry.

CBP/p300 drives the differentiation of Regulatory T cells through transcriptional and non-transcriptional mechanisms.

W. Jones, K. Hutchinson, J. Giltnane, 2019, Cancer research.

Optimization of α -Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

D. Boger, F. A. Romero, C. Ezzili, 2009 .

Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.

F. A. Romero, F. Ujjainwalla, A. Howard, 2018, ACS medicinal chemistry letters.

GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1.

A. Good, P. Sandy, Y. Leblanc, 2022, Journal of medicinal chemistry.

GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).

P. Sandy, H. Jayaram, R. Sims, 2017, ACS medicinal chemistry letters.

Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.

Fei Wang, F. A. Romero, E. Choo, 2018, Bioorganic & medicinal chemistry letters.

Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300.

Karen E Gascoigne, Fei Wang, S. Kharbanda, 2016, Journal of medicinal chemistry.

Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

D. Boger, B. Cravatt, F. A. Romero, 2007 .

Total synthesis of piericidin A1 and B1 and key analogues.

D. Boger, T. Yagi, F. A. Romero, 2006, Journal of the American Chemical Society.

Delineation of a fundamental alpha-ketoheterocycle substituent effect for use in the design of enzyme inhibitors.

D. Boger, F. A. Romero, I. Hwang, 2006, Journal of the American Chemical Society.

Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase.

D. Boger, Heather S Hoover, B. Cravatt, 2007, Journal of medicinal chemistry.

A one-pot three-component reaction to access 1-alkyl-2-aryl-5-nitrobenzimidazoles under solvent-free conditions

F. A. Romero, Remond Moningka, 2010 .

Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation.

Karen E Gascoigne, S. Kharbanda, R. Raisner, 2018, Cell reports.

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.

F. A. Romero, Alexander M. Taylor, A. Côté, 2016, Journal of medicinal chemistry.

Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer.

Karen E Gascoigne, Z. Modrušan, S. Kharbanda, 2017, Cancer research.

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition*

G. Hatzivassiliou, P. Sandy, H. Jayaram, 2016, The Journal of Biological Chemistry.

An efficient method to access 2-substituted benzimidazoles under solvent-free conditions

F. A. Romero, P. Lan, G. Makara, 2008 .

GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP).

Karen E Gascoigne, Y. Ran, G. Hatzivassiliou, 2017, Journal of medicinal chemistry.

Optimization of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.

Dale L Boger, D. Boger, F. A. Romero, 2008, Journal of medicinal chemistry.

Structure-activity relationships of alpha-ketooxazole inhibitors of fatty acid amide hydrolase.

D. Boger, B. Cravatt, F. A. Romero, 2007, Journal of medicinal chemistry.

Discovery of MK-8722: A Systemic, Direct Pan-Activator of AMP-Activated Protein Kinase.

D. Kemp, Gaochao Zhou, F. A. Romero, 2018, ACS medicinal chemistry letters.

Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase.

Margaret S. Wu, Q. Dang, D. Mackenna, 2017, Journal of medicinal chemistry.

Exploring the active site of phenylethanolamine N-methyltransferase with 3-hydroxyethyl- and 3-hydroxypropyl-7-substituted-1,2,3,4-tetrahydroisoquinolines.

D. Bylund, F. A. Romero, Mitchell R Seim, 2005, Bioorganic & medicinal chemistry letters.

Preclinical Safety Assessment of a Highly Selective and Potent Dual Small-Molecule Inhibitor of CBP/P300 in Rats and Dogs

F. A. Romero, G. Cain, E. Choo, 2020, Toxicologic pathology.

Exploring the active site of phenylethanolamine N-methyltransferase: 3-alkyl-7-substituted-1,2,3,4-tetrahydroisoquinoline inhibitors.

F. A. Romero, G. L. Grunewald, K. R. Criscione, 2005, Bioorganic & medicinal chemistry.